{"analyses":[{"groupIds":["OG000"],"nonInferiorityComment":"The PFS function was estimated using the Kaplan-Meier product-limit method, a non-parametric statistic.","nonInferiorityType":"OTHER","otherAnalysisDescription":"The PFS function was estimated using the Kaplan-Meier product-limit method. Median and one-sided confidence intervals (CIs) for PFS were computed and Kaplan-Meier plots of PFS were developed."}],"classes":[{"categories":[{"measurements":[{"comment":"The upper limit was never reached (NR).","groupId":"OG000","lowerLimit":"5.5","upperLimit":"NA","value":"24.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"Overall survival was defined as the time, in months, from the first dose of therapy to the date of death from any cause.","dispersionType":"95% Confidence Interval","groups":[{"description":"Daratumumab:\n\nDaratumumab was given at a dose of 16 mg/kg administered as an intravenous (IV) infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter. Dexamethasone was administered according to the standard recommended dose of 40 mg (20 mg for patients \\> 75 years of age) orally once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle. Subjects received pre-infusion medications before infusions to mitigate potential infused-related reactions (IRRs).\n\nDexamethasone:\n\nDexamethasone was administered at 40 mg (20 mg for patients \\> 75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.","id":"OG000","title":"Single Arm Trial Receiving Daratumumab With Dexamethasone (DaraD)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Time from first dose of study treatment to death (approximately up to 30 months)","title":"Overall Survival","type":"SECONDARY","unitOfMeasure":"Months"}